ITPA genotype protects against anemia during peginterferon and ribavirin therapy but does not influence virological response

Holmes, Jacinta A.
Roberts, Stuart K.
Ali, Rachel J.
Dore, Gregory J.
Sievert, William
McCaughan, Geoffrey W.
Crawford, Darrell H.
Cheng, Wendy S.
Weltman, Martin D.
Bonanzinga, Sara
Visvanathan, Kumar
Sundararajan, Vijaya
Desmond, Paul V.
Bowden, D. Scott
Matthews, Gail V.
Thompson, Alexander J.

Open link

Publication date

June 2014

DOI

10.1002/hep.27022

Publisher

Wiley

ISSN

0270-9139

Citation count (estimate)

Abstract

On-treatment anemia is associated with higher sustained virological response (SVR) rates during peginterferon plus ribavirin (RBV) therapy. Inosine triphosphatase (ITPA) variants causing ITPase deficiency have been shown to protect against RBV-induced anemia. However, ITPase activity has not been associated with SVR. To study this discrepancy, we examined the relationships between ITPase activity, on-treatment anemia, SVR, and RBV levels in hepatitis C virus genotype 1 (HCV-1) patients from the CHARIOT study. ITPA genotype (rs7270101, rs1127354) was used to define ITPase activity in 546 patients. Plasma RBV levels were measured using high-performance liquid chromatography (HPLC). Relationships between ITPase activity, on-treatment hemoglobi...